Safety and efficacy of dexpramipexole in eosinophilic asthma: a comparative study in a tertiary care hospital in Bangladesh
DOI:
https://doi.org/10.18203/2320-6012.ijrms20251615Keywords:
Eosinophilic, Dexpramipexole, Eosinophil, Lung, Function, Volume, Exacerbation, AsthmaAbstract
Introduction: Eosinophilic asthma is characterized by elevated eosinophil levels and frequent exacerbations, which are difficult to control with standard therapies. Dexpramipexole, an oral small molecule, has shown promise in reducing eosinophil counts, but data on its long-term efficacy and safety are limited. This study aimed to evaluate the efficacy and safety of Dexpramipexole in patients with eosinophilic asthma, focusing on changes in blood eosinophil counts, lung function, quality of life, and asthma exacerbation rates.
Methods: This was a cross-sectional observational comparative study conducted at the department of Reparatory Medicine during January-2021 to December-2021, in Uttara Adhunik Medical College Hospital, Dhaka Bangladesh. A total of 200 confirmed cases with eosinophilic asthma were purposively employed to receive Dexpramipexole (n=100) and placebo (n=100) for 12 months follow up. The collected data were analyzed using Statistical Package for Social Sciences (SPSS), version-23.0.
Results: The Dexpramipexole group achieved a 75% reduction in eosinophil counts compared to 12% in the placebo group (p<0.001). FEV1 improved by 15% in the Dexpramipexole group versus 2% in the placebo group (p<0.01). Quality of life scores increased by 1.5 points compared to 0.3 points in the placebo group (p<0.001). A 30% reduction in asthma exacerbations was observed (p=0.03).
Conclusion: Dexpramipexole demonstrated significant improvements in eosinophil reduction, lung function, quality of life, and exacerbation rates over a 12-months period, with a favorable safety profile. These results suggest Dexpramipexole may be a promising long-term therapeutic option for eosinophilic asthma.
Metrics
References
Hussain M, Liu G. Eosinophilic Asthma: pathophysiology and Therapeutic Horizons. Cells. 2024;13(5):384. DOI: https://doi.org/10.3390/cells13050384
McBrien CN, Menzies-Gow A. The biology of eosinophils and their role in asthma. Frontiers Medicine. 2017;4:93. DOI: https://doi.org/10.3389/fmed.2017.00093
Asano K, Suzuki Y, Tanaka J, Kobayashi K, Kamide Y. Treatments of refractory eosinophilic lung diseases with biologics. Allergol Int. 2023;72(1):31-40. DOI: https://doi.org/10.1016/j.alit.2022.10.004
Seluk L, Davis AE, Rhoads S, Wechsler ME. Novel asthma treatments: advancing beyond approved novel step-up therapies for asthma. Ann Aller, Asthma Immunol. 2024;2:783-6.
Kuang FL. Dexpramipexole: a potential non-biologic alternative for patients with eosinophilic asthma. Reviews In Resp Pulm Dis. 2022;7(2):94. DOI: https://doi.org/10.17925/USRPD.2022.7.2.36
Siddiqui S, Wenzel SE, Bozik ME, Archibald DG, Dworetzky SI, Mather JL, et al. Safety and efficacy of dexpramipexole in eosinophilic asthma (EXHALE): a randomized controlled trial. J Allergy Clin Immunol. 2023;152(5):1121-30.
Tiotiu A. Biomarkers in asthma: state of the art. Asthma Res Pract. 2018;4(1):10. DOI: https://doi.org/10.1186/s40733-018-0047-4
Labrosse R, Haddad E. Immunodeficiency secondary to biologics. J Allergy Clin Immunol. 2023;151(3):686-90. DOI: https://doi.org/10.1016/j.jaci.2023.01.012
Halsey G. Dupilumab becomes first biologic approved in the us as targeted therapy for adults with COPD. Patient Care. 2024;3:89-92.
Louis G, Pétré B, Schleich F, Zahrei HN, Donneau AF, Henket M, Paulus V, Guissard F, Guillaume M, Louis R. Predictors of change in asthma-related quality of life: a longitudinal real-life study in adult asthmatics. Qual Life Res. 2023;32(5):1507-20. DOI: https://doi.org/10.1007/s11136-022-03339-0
Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835-52. DOI: https://doi.org/10.1080/1744666X.2021.1940962
Abuelhassan UE, Al-Mani SY, Alqahtani SM, Elnamaky M, Alfaifi A, Alshehri MA, et al. Impact of biological therapies on laboratory outcomes and FEV1 in patients with severe eosinophilic asthma with chronic rhinosinusitis: a real-life study from Saudi Arabia. Multidisciplinary Respiratory Med. 2024;19(1):985. DOI: https://doi.org/10.5826/mrm.2024.985
Laidlaw TM, Prussin C, Panettieri RA, Lee S, Ferguson BJ, Adappa ND, et al. Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size. Laryngos. 2019;129:61-6. DOI: https://doi.org/10.1002/lary.27564
Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019;200:70-88. DOI: https://doi.org/10.1164/rccm.201908-1590ST
Makiya MA, Khoury P, Kuang FL, Mata AD, Mahmood S, Bowman A, et al. Urine eosinophil-derived neurotoxin: a potential marker of activity in select eosinophilic disorders. Allergy. 2023;78:258-69. DOI: https://doi.org/10.1111/all.15481
Nair P, Ochkur SI, Protheroe C, Radford K, Efthimiadis A, Lee NA, et al. Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. Allergy. 2013;68:1177-84. DOI: https://doi.org/10.1111/all.12206
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-6. DOI: https://doi.org/10.1016/S0140-6736(12)60988-X
Siddiqui S, Wenzel SE, Bozik ME, Archibald DG, Dworetzky SI, Mather JL, et al. Safety and efficacy of dexpramipexole in eosinophilic asthma (EXHALE): a randomized controlled trial. J Allergy Clin Immunol. 2023;152(5):1121-30. DOI: https://doi.org/10.1016/j.jaci.2023.05.014
Dworetzky SI, Hebrank GT, Archibald DG, Reynolds IJ, Farwell W, Bozik ME. The targeted eosinophil-lowering effects of dexpramipexole in clinical studies. Blood Cells Mol Dis. 2017;63:62-5. DOI: https://doi.org/10.1016/j.bcmd.2017.01.008
Panch SR, Bozik ME, Brown T, Makiya M, Prussin C, Archibald DG, et al. Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood. 2018;132:501-9. DOI: https://doi.org/10.1182/blood-2018-02-835330
Downloads
Published
How to Cite
Issue
Section
